Creating a new device to measure phosphate levels in patients with kidney disease
Development of a minimally invasive optical biosensor to improve hyperphosphatemia management
This study is working on a new, easy-to-use device that helps people with chronic kidney disease keep track of their phosphate levels in real-time, making it easier for them and their doctors to manage their health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Engineering Experiment Station NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10742278 on NIH RePORTER |
What this research studies
This research focuses on developing a minimally invasive optical biosensor designed to continuously monitor phosphate levels in patients with chronic kidney disease (CKD) and end-stage kidney disease. By using hydrogel composites and biosensor particles, the device aims to provide real-time data on serum phosphate concentrations, which are crucial for managing hyperphosphatemia. The project includes both laboratory testing to refine the sensor's accuracy and in vivo testing to ensure its effectiveness in a clinical setting. This innovative approach seeks to empower both patients and healthcare providers with better tools for managing this serious condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic kidney disease or end-stage kidney disease who experience elevated phosphate levels.
Not a fit: Patients with normal kidney function or those not experiencing issues with phosphate levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of hyperphosphatemia, reducing cardiovascular risks for patients with kidney disease.
How similar studies have performed: While the approach of using optical biosensors for monitoring biochemical levels is promising, this specific application for phosphate monitoring in CKD patients is relatively novel.
Where this research is happening
College Station, United States
- Texas Engineering Experiment Station — College Station, United States (Active)
Researchers
- Principal investigator: Alge, Daniel — Texas Engineering Experiment Station
- Study coordinator: Alge, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.